SG191154A1 - Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof - Google Patents
Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Download PDFInfo
- Publication number
- SG191154A1 SG191154A1 SG2013045737A SG2013045737A SG191154A1 SG 191154 A1 SG191154 A1 SG 191154A1 SG 2013045737 A SG2013045737 A SG 2013045737A SG 2013045737 A SG2013045737 A SG 2013045737A SG 191154 A1 SG191154 A1 SG 191154A1
- Authority
- SG
- Singapore
- Prior art keywords
- seq
- peptides
- hla
- peptide
- composition
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 20
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 11
- 238000000034 method Methods 0.000 title claims abstract 6
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 210000002307 prostate Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 19
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 8
- 239000000568 immunological adjuvant Substances 0.000 claims abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 238000009167 androgen deprivation therapy Methods 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4276—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/069675 WO2011073215A2 (en) | 2009-12-14 | 2010-12-14 | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| PCT/EP2011/070024 WO2012079878A2 (en) | 2010-12-14 | 2011-11-14 | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG191154A1 true SG191154A1 (en) | 2013-07-31 |
Family
ID=44983532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013045737A SG191154A1 (en) | 2010-12-14 | 2011-11-14 | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
Country Status (9)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013012432A1 (de) * | 2013-07-29 | 2015-01-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immuntherapie von Prostatakrebs |
| MX384635B (es) * | 2014-04-16 | 2025-03-14 | Biosimilars Newco Ltd | Formulaciones de proteína estables que comprenden un exceso molar de sorbitol. |
| EP3845557B1 (en) * | 2015-06-12 | 2023-08-02 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN116693695A (zh) * | 2017-02-12 | 2023-09-05 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA725596A (en) | 1960-08-26 | 1966-01-11 | J. Wretlind Arvid | Method of preparing intravenously injectable fat emulsions free from side reactions or complications |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| JP2003521245A (ja) * | 1999-12-21 | 2003-07-15 | エピミューン， インコーポレイテッド | ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導 |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20020081680A1 (en) * | 2000-04-17 | 2002-06-27 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| AU2003217421A1 (en) * | 2002-02-19 | 2003-09-09 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
| US7906620B2 (en) * | 2002-08-16 | 2011-03-15 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| US20060205934A1 (en) * | 2002-12-05 | 2006-09-14 | Macina Roberto A | Compositions, splice variants and methods relating to breast specific genes and proteins |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| WO2006023598A2 (en) * | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| DE602004019215D1 (de) | 2004-10-02 | 2009-03-12 | Immatics Biotechnologies Gmbh | Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden |
| EP1806358B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| PT2113253E (pt) * | 2008-04-30 | 2010-06-15 | Immatics Biotechnologies Gmbh | Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas |
| EP2119726B2 (en) * | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
-
2011
- 2011-11-14 CN CN201180059274.2A patent/CN103547283A/zh active Pending
- 2011-11-14 MX MX2013006758A patent/MX2013006758A/es unknown
- 2011-11-14 WO PCT/EP2011/070024 patent/WO2012079878A2/en active Application Filing
- 2011-11-14 JP JP2013543601A patent/JP6032853B2/ja not_active Expired - Fee Related
- 2011-11-14 CA CA2821582A patent/CA2821582A1/en not_active Abandoned
- 2011-11-14 NZ NZ60991611A patent/NZ609916A/en not_active IP Right Cessation
- 2011-11-14 KR KR1020137018147A patent/KR20130126671A/ko not_active Withdrawn
- 2011-11-14 AU AU2011344652A patent/AU2011344652B2/en not_active Ceased
- 2011-11-14 SG SG2013045737A patent/SG191154A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2821582A1 (en) | 2012-06-21 |
| NZ609916A (en) | 2015-03-27 |
| AU2011344652A1 (en) | 2013-05-23 |
| CN103547283A (zh) | 2014-01-29 |
| JP2014502961A (ja) | 2014-02-06 |
| JP6032853B2 (ja) | 2016-11-30 |
| AU2011344652B2 (en) | 2015-11-19 |
| WO2012079878A2 (en) | 2012-06-21 |
| MX2013006758A (es) | 2013-08-01 |
| WO2012079878A3 (en) | 2012-08-09 |
| KR20130126671A (ko) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9023802B2 (en) | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| US9023804B2 (en) | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| AU2011344652B2 (en) | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| US9132177B2 (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| CA2817054C (en) | Composition of tumour-associated peptides and related anti-cancer vaccine | |
| CA2739384C (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers | |
| EP2651434A2 (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| Class et al. | Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH | |
| HK1180701B (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |